STAY INFORMED. VISIT NHIA.ORG/COVID19 FOR INFORMATION AND RESOURCES ABOUT CORONAVIRUS DISEASE (COVID-19).
Be part of NHIF’s benchmarking program to collect industry-wide, standardized data to establish a national reference point for performance and clinical metrics.
NHIA has developed product shortage recommendations to help clinicians manage patients during this time when diluents, and small and large volume parenteral solutions may not be readily available.
The groups ask regulators to assess the impact of these businesses on critical drug shortages and for states to regulate them appropriately.
Ambulatory infusion pump sets for use in the United States are in limited supply. NHIA has developed product shortage recommendations to help clinicians manage patients during this time when pump sets may not be readily available.
CMS issued the Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) final rule and is not finalizing its interpretation of the “appropriate for use in the home” requirement in the definition of DME as it applies to certain external infusion pumps.
Please know that NHIA is here to help in whatever ways we can. If your organization is struggling to source supplies, arrange for alternative patient care, understand how emergency declarations and waivers impact your operations, or anything else, feel free to reach out to us.
With Eitan Medical’s global footprint, this strategic partnership expands the international presence within the advisory group and will inform the discussion around bringing connected technology solutions to the home and alternate site infusion industry.
Learn about the new LCDs, what it means for home PEN patients and home providers and the challenges that still exist in home PEN Medicare coverage which will require advocacy from NHIA, ASPEN, home care clinicians and patients.
This strategic partnership between NHIA and PlayMaker Health will bring a unique perspective to the FIAC, adding support for data-driven programs critical to expanding access of home and alternate site infusion.
